// App-Quantinova.ai

: ACTR-71. PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA

Researchers

Presenter

  • Zhong-ping Chen

Principal Investigators

  • Chengcheng Guo

  • Jeffrey Bacha

  • Anne Steino

  • John Langlands

  • Claire Kwan

  • Sarath Kanekal

  • Richard Schwartz

  • Lorena Lopez

  • Dennis Brown

Medical Centers

  • Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Del Mar Pharmaceuticals, Vancouver, BC, Canada

  • DelMar Pharmaceuticals, San Francisco, CA.

  • Adastra Pharmaceuticals, Inc, San Diego, CA, USA

Locations

  • China

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cerebrospinal fluid

Drug/Treatment

  • Dianhydrogalactitol

  • Temozolomide

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03050736

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved